RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement

RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/17/14 --  
RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (TSX
VENTURE: RP)(OTCQB: REPCF), is pleased to announce it has completed
the third and final tranche of its non-brokered financing (the
"Financing") announced on March 28, 2014, which consisted of a
non-brokered private placement of 866,000 units (each a "Unit") at a
price of $0.75 per Unit for gross proceeds of $649,500 (the
"Offering"). The total final gross proceeds for the Unit offering
were $3,990,125.25. Each Unit consists of one common share of the
Company (each, a "Share") and one Share purchase warrant (the
"Warrant"), which will entitle the holder to purchase one additional
Share for a period of two years from the closing of the private
placement at a price of $1.00 per Share during the first year and
$1.25 per Share during the second year. This financing was led by
Crossover Healthcare Fund, LLC.  
"This financing puts us in a position to execute on our near-term
clinical initiatives towards the commercialization of RCT-A-01, a
treatment for chronic Achilles tendinosis, RCS-01, a treatment for
aging and sun damaged skin and RCH-01, a treatment for pattern
baldness. All three trials are on track for filing this year which
will drive key six month data next year for RCT-A-01 and RCS-01.
Launching three human clinical trials running concurrently will be a
significant accomplishment for a biotech company of our size. To our
knowledge, there are only a handful of publically traded companies in
the regenerative medicine sector that are doing this," stated David
Hall, CEO of RepliCel. He goes on to say, "We are especially excited
to have the participation of Crossover Healthcare Fund LLC in this
last tranche of financing. The Crossover Healthcare Fund, led by
Navroze Alphonse and Dr. John P. Nicholson Jr., is a strategic new
life science focused Boston-based shareholder who we look forward to
working with as we rapidly broaden our exposure to the US healthcare
investment community."  
All securities issued in the financing will be subject to a statutory
hold period expiring four months and one day after closing of the
financing. None of the securities issued in the financing have been
registered under the United States Securities Act of 1933, as amended
(the "1933 Act"), and none of them may be offered or sold in the
United States absent registration or an applicable exemption from the
registration requirements of the 1933 Act. This press release shall
not constitute an offer to sell or a solicitation of an offer to buy
nor shall there be any sale of the securities in any state where such
offer, solicitation, or sale would be unlawful.  
Further to its news release dated May 9, 2014, the Company also
announces that in connection with the closing of the first tranche of
the financing, the Company issued additional finder's warrants to
purchase 42,800 Shares at a price of $0.75 per Share for a period of
24 months to one finder. 
About RepliCel Life Sciences 
RepliCel is a regenerative medicine company focused on developing
autologous cell therapies that address diseases caused by a deficit
of healthy cells required for normal healing and function such as
chronic tendinosis, damaged skin and pattern baldness. The company's
RCT-01 and RCS-01 cell therapies are designed to treat chronic
tendinosis and damaged or aging skin respectively, using fibroblasts
isolated from the sheath of the hair follicle. Another of the
company's pipeline products, RCH-01 for the treatment of pattern
baldness, is manufactured from cells derived from the hair follicle
dermal cup. Shiseido Company, Limited has an exclusive geographic
license for RCH-01 in certain Asian countries including Japan, China
and South Korea. All product candidates are based on RepliCel's
innovative technology which utilizes cells isolated from a patient's
own healthy hair follicles to address specific cellular deficits. For
additional information please visit 
Neither the TSX Venture Exchange Inc. nor its Regulation Service
Provider (as that term is defined in the policies of the TSX Venture
Exchange Inc.) accepts responsibility for the adequacy or accuracy of
this press release. 
This press release contains forward-looking information that involve
various risks and uncertainties regarding future events, including
statements regarding the Company's belief that the proceeds from the
financing puts the Company in a position to execute on its clinical
incentives, the timing of trials, and the Company broadening its
exposure into the US healthcare investment community. Such
forward-looking information can include without limitation statements
based on current expectations involving a number of risks and
uncertainties and are not guarantees of future performance of
RepliCel. There are numerous risks and uncertainties that could cause
actual results and RepliCel's plans and objectives to differ
materially from those expressed in the forward-looking information,
including: negative results from the Company's clinical trials; the
effects of government regulation on the Company's business; risks
associated with the Company's ability to obtain and protect rights to
its intellectual property; risks and uncertainties associated with
the Company's ability to raise additional capital; and other factors
beyond the Company's control. Actual results and future events could
differ materially from those anticipated in such information. These
and all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, RepliCel does not intend to update these
forward-looking statements. 
RepliCel Life Sciences Inc.
David M. Hall
Chief Executive Officer 
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
Christina Cameron
Press spacebar to pause and continue. Press esc to stop.